Epilepsy Alliance America Announces SK Life Science Inc. Will Support Its Mission to Provide Epilepsy Care, Support and Education

Baton Rouge, LA, July 20, 2021 – Epilepsy Alliance America, a nationwide network of community-based epilepsy organizations dedicated to providing direct care, education and support services to people living with epilepsy and the people who care for them, today announced that SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., a global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, will support its goal of advancing nationwide programs to confront the spectrum of challenges created by seizures.

SK life science will support Epilepsy Alliance America as the marquee sponsor of select fundraising walks, runs, events, galas and community outreach programs that make it possible for EAA to provide vital day-to-day support, care, education and services to people with epilepsy in local communities across the U.S.

As a part of the mission to provide resources for those with epilepsy and their loved ones as they advocate for their treatment goals, Epilepsy Alliance America is sharing a digital library of resources, including tools to facilitate meaningful conversations among patients, caregivers and doctors about care plans. The S.T.E.P.S. discussion guide, which was developed by SK life science based on findings from a nationwide survey, is available at www.epilepsyallianceamerica.org/steps-tool/.

“We are proud to collaborate with SK life science, a company that shares our mission to support the lives of people with epilepsy and their loved ones in local communities across the country,” stated Jeff Sinsebox, President of Epilepsy Alliance America. “As we continue to expand our education, care and support services to our member organizations and the millions of patients and their caregivers, I look forward to sharing knowledge and resources to better address the needs of people with epilepsy and their loved ones.”

“The fight against epilepsy takes a shared sense of urgency and commitment to action, and we’re proud to work together with the Epilepsy Alliance America on a national level as they provide direct support for epilepsy communities,” said Louis Ferrari, Vice President of Medical Affairs at SK life science. “We know living with epilepsy is more than seizures and that’s why we’ve created new tools like the S.T.E.P.S. discussion guide to encourage the community to have broader conversations and inspire patients to discuss their personal treatment goals with their care team.”

About the Epilepsy Alliance America
Epilepsy Alliance America is a nationwide network of community-based epilepsy organizations who are dedicated to confronting the spectrum of challenges created by seizures through the promotion of independence and quality of life for people with epilepsy and their families. Epilepsy Alliance America was founded in 2018 by eight leading grassroots epilepsy organizations who have unified in their mission to provide direct support to people with epilepsy, and the people who care for them.
Members of Epilepsy Alliance America have been collectively supporting people with epilepsy for decades through support services, information, education, advocacy and public awareness. As a result, the Alliance provides real epilepsy help to approximately 1 million Americans living with epilepsy.

For more information, visit the Epilepsy Alliance America website at www.epilepsyallianceamerica.org

About SK Biopharmaceuticals Co., Ltd. and SK Life Science, Inc.
SK Biopharmaceuticals and its U.S. subsidiary SK life science are global pharmaceutical companies focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). The companies have a pipeline of eight compounds in development for the treatment of CNS disorders, including epilepsy. Additionally, SK Biopharmaceuticals is focused on early research in oncology. For more information, visit SK Biopharmaceuticals’ website at www.skbp.com/eng and SK life science’s website at www.SKLifeScienceInc.com.

Both SK Biopharmaceuticals and SK life science are part of SK Group, one of the largest conglomerates in Korea. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information, please visit http://hc.sk.co.kr/en/.